Fexofenadine dihydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577015

CAS#: 885946-90-7

Description: Fexofenadine dihydrate is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever, nasal congestion, and urticaria. Fexofenadine is classified as a second-generation antihistamine because it is less able to pass the blood-brain barrier and cause sedation, compared to a first-generation antihistamines.

Chemical Structure

img
Fexofenadine dihydrate
CAS# 885946-90-7
Instruction

Theoretical Analysis

MedKoo Cat#: 577015
Name: Fexofenadine dihydrate
CAS#: 885946-90-7
Chemical Formula: C32H43NO6
Exact Mass: 537.31
Molecular Weight: 537.700
Elemental Analysis: C, 71.48; H, 8.06; N, 2.60; O, 17.85

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Fexofenadine dihydrate

IUPAC/Chemical Name: 2-(4-{1-Hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid dihydrate

InChi Key: PBHJQUWFAKHMIX-UHFFFAOYSA-N

InChi Code: InChI=1S/C32H39NO4.2H2O/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);2*1H2

SMILES Code: CC(C)(C1=CC=C(C(O)CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2)C=C1)C(O)=O.[H]O[H].[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 537.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yao M, Srinivas NR. Quantification of fexofenadine in biological matrices: a review of bioanalytical methods. Biomed Chromatogr. 2012 Aug;26(8):942-61. doi: 10.1002/bmc.2712. Epub 2012 Feb 21. Review. PubMed PMID: 22354834.

2: Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Arch Allergy Immunol. 2011;156(1):1-15. Review. PubMed PMID: 21969990.

3: Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Review. PubMed PMID: 19947891.

4: Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967. Review. PubMed PMID: 19545214.

5: Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. Review. PubMed PMID: 19539095.

6: Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. Review. PubMed PMID: 18336052.

7: Mansfield LE. Fexofenadine in pediatrics: oral tablet and suspension formulations. Expert Opin Pharmacother. 2008 Feb;9(2):329-37. doi: 10.1517/14656566.9.2.329 . Review. PubMed PMID: 18201155.

8: Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D. 2007;8(5):301-14. Review. PubMed PMID: 17767395.

9: Mansfield LE. Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis. Expert Opin Pharmacother. 2006 May;7(7):941-51. Review. PubMed PMID: 16634716.

10: Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. Review. PubMed PMID: 15312146.

11: Ciprandi G, Tosca MA, Cosentino C, Riccio AM, Passalacqua G, Canonica GW. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S78-82. Review. PubMed PMID: 14530792.

12: Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S69-77. Review. PubMed PMID: 14530791.

13: Kawashima M, Harada S, Tango T. Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol. 2002 Oct;41(10):701-6. Review. PubMed PMID: 12390200.

14: Amichai B, Grunwald MH, Brenner L. Fexofenadine hydrochloride--a new anti-histaminic drug. Isr Med Assoc J. 2001 Mar;3(3):207-9. Review. PubMed PMID: 11303380.

15: Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999 Jul;29 Suppl 3:163-70; discussion 171-3. Review. PubMed PMID: 10444232.

16: Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol. 1999 May 15;83(10):1451-4. Review. PubMed PMID: 10335761.

17: Markham A, Wagstaff AJ. Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. Review. PubMed PMID: 9506246.